Skip to content
Wednesday, November 11, 2026
Explore the latest in UK tech trends, digital innovation, a…

Individuals Stopping Anti-Obesity Injections Regain Pounds at a Quadrupled Rate Compared to Dieters

Illustration of medical injection and weighing machine
Weight management often requires ongoing approaches.

Fresh analysis suggests that patients who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who halt conventional diet and exercise programs.

Findings released in a major health publication points out that while obese people frequently drop about a fifth of their total mass while undergoing treatment, the weight returns at an average rate of nearly a kilo each month upon discontinuation.

"Users using such medications must be cognizant of the danger of fast weight regain when the treatment ends," warns expert Dr. Susan Jebb.

Such speed of regain implies a reversion to pre-treatment weight within about one and a half years.

Analyzing Treatments

The analysis, which looked at 37 of trials involving over 9,000 of patients, contrasted the results of GLP-1 agonists with conventional dieting.

Scientists emphasize that individuals who lose weight through diet and exercise typically see a slower weight regain—around 100 grams monthly—after stopping.

The Reason for the Fast Regain

Nutrition scientists propose the way of the injections is key to understanding the amplified weight return.

GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.

"Long-term administration of the hormone levels several times higher than the body's typical production could lead to the body to generate a reduced amount of its own natural GLP-1, and could lessen sensitivity to its actions," said Dr. Adam Collins, a dietetics expert.

"Stopping of this hormone supplement leads to appetite is unsuppressed, making overeating much more probable."

A Chronic Issue?

Medical guidelines suggest the injections for individuals with obesity-related health risks, alongside prescribed lifestyle changes.

Many experts say that, given the significant potential of relapse, the treatment should be considered ongoing.

This view is echoed by drug manufacturers, who state that the results "emphasize the long-term character of obesity," akin to managing diseases like high blood pressure.

Patient Experiences

Individuals who have discontinued the jabs explain a intense resurgence of appetite.

"I experienced a trigger activating and you're instantly starving," recalled a patient.

This difficulty is exacerbated if patients have not established sustainable lifestyle or habit modifications during therapy.

Widespread Interest

Recent estimates suggest that a significant number of people in the UK have used weight-loss jabs in the past year, with interest being substantial.

  • Use is greater among women than men.
  • The 40s and 50s demographic shows the highest level of interest.
  • A large proportion access the drugs through private healthcare rather than the NHS.

In conclusion, experts stress that while GLP-1 drugs are effective agents for weight loss, they are not a permanent fix and maintained weight loss likely depends on ongoing lifestyle management.

The writer

Daniel Orozco

A tech journalist and digital strategist with over a decade of experience covering UK innovation and startup ecosystems.

Corner Open UK

Type to search articles.